12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation

June 1, 2007 updated by: Pfizer

A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of CP-526,555 In Smokers Motivated To Stop Smoking

The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-treatment follow-up of smoking status to one year from randomization. A small satellite protocol (A3051048) investigated safety of a second course of therapy in subjects who did not quit.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment

600

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Fukuoka, Japan
        • Pfizer Investigational Site
      • Ohita, Japan
        • Pfizer Investigational Site
    • Chiba
      • Noda, Chiba, Japan
        • Pfizer Investigational Site
    • Hokkaido
      • Sapporo, Hokkaido, Japan
        • Pfizer Investigational Site
    • Kanagawa
      • Yokohama, Kanagawa, Japan
        • Pfizer Investigational Site
    • Oita-ken
      • Beppu-shi, Oita-ken, Japan
        • Pfizer Investigational Site
    • Osaka
      • Toyonaka, Osaka, Japan
        • Pfizer Investigational Site
    • Saga
      • Tosu, Saga, Japan
        • Pfizer Investigational Site
    • Shizuoka
      • Hamamatsu, Shizuoka, Japan
        • Pfizer Investigational Site
    • Tokyo
      • Edogawa-ku, Tokyo, Japan
        • Pfizer Investigational Site
      • Minato-ku, Tokyo, Japan
        • Pfizer Investigational Site
      • Musashino, Tokyo, Japan
        • Pfizer Investigational Site
      • Setagaya-ku, Tokyo, Japan
        • Pfizer Investigational Site
      • Shinagawa-ku, Tokyo, Japan
        • Pfizer Investigational Site
      • Toshima-ku, Tokyo, Japan
        • Pfizer Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Cigarette smokers who are motivated to stop smoking and have smoked an average of at least 10 cigarettes per day

Exclusion Criteria:

  • Subjects who have used a nicotine replacement product within 30 days of the study screening visit or intend to use it during the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
4-week continuous quit rate (CQR) for Weeks 9-12

Secondary Outcome Measures

Outcome Measure
Continuous abstinence for Weeks 9-52 and Weeks 9-24
Long-term quit rate at Week 52
4-week CQR for Weeks 4-7
7-day point prevalence of asbtinence Weeks 12, Week 24, and Week 52
Continuous abstinence from TQD (Week 1) through Week 12
Weekly average number of cigarettes smoked per day for Weeks 1-12
Evaluation of withdrawal symptoms by the Minnesota Nicotine Withdrawal Scale
Evaluation of smoking satisfaction by the Smoking Effects Inventory
Evaluation of urge to smoke by the Brief Questionnaire of Smoking Urges

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2004

Study Completion (Actual)

February 1, 2006

Study Registration Dates

First Submitted

August 29, 2005

First Submitted That Met QC Criteria

August 30, 2005

First Posted (Estimate)

August 31, 2005

Study Record Updates

Last Update Posted (Estimate)

June 4, 2007

Last Update Submitted That Met QC Criteria

June 1, 2007

Last Verified

June 1, 2007

More Information

Terms related to this study

Other Study ID Numbers

  • A3051046

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.